Overview A Phase I Study of GT300 in Healthy Subjects Status: Not yet recruiting Trial end date: 2022-03-15 Target enrollment: Participant gender: Summary Descriptive safety and pharmacokinetics of GT300, exploratory biomarker effects for the evaluation of the effect of GT300 on the autophagy-lysosomal pathway (ALP), food effect on PK and fasting effect on biomarkers. Phase: Phase 1 Details Lead Sponsor: Generian Pharmaceuticals, Inc.